Algorithm Pipeline
Innovative diagnostic tools for detecting rare and hidden disease, based on the world’s largest labeled patient dataset, built to be integrated into existing physician workflows and currently pursuing FDA approval.
Program
Development
Pre-Submission
Validation
Submission
Approval
Low Ejection Fraction
Granted FDA Breakthrough Device Designation
Pulmonary Hypertension
Granted FDA Breakthrough Device Designation
Hyperkalemia
Granted FDA Breakthrough Device Designation
Hypertrophic Cardiomyopathy
Amyloidosis
Atrial Fibrillation in Normal Sinus Rhythm
Aortic Stenosis
Myocarditis
Early Stage Development Programs
Low Ejection Fraction
Granted FDA Breakthrough Device Designation
Phase: Validation
Pulmonary Hypertension
Granted FDA Breakthrough Device Designation
Phase: Development
Hyperkalemia
Granted FDA Breakthrough Device Designation
Phase: Development
Hypertrophic Cardiomyopathy
Phase: Development
Amyloidosis
Phase: Development
Atrial Fibrillation in Normal Sinus Rhythm
Phase: Development
Aortic Stenosis
Phase: Development
Myocarditis
Phase: Development
Early Stage Development Programs
Phase: Development
Partner with us!
We’re actively developing algorithms for FDA approval. Please direct partnership and media inquiries to info@anumana.net
@2022 anumana, Inc. All rights reserved.